BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

Journal of Experimental Medicine

Volumn 211, Issue 4, 2014, Pages 669-683

  Berres, Marie Luise ^a   Lim, Karen Phaik Har ^b   Peters, Tricia ^c   Price, Jeremy ^a   Takizawa, Hitoshi ^d   Salmon, Hélène ^a   Idoyaga, Juliana ^e   Ruzo, Albert ^e   Lupo, Philip J ^b,c   Hicks, M John ^c   Shih, Albert ^b   Simko, Stephen J ^b,c   Abhyankar, Harshal ^b,c   Chakraborty, Rikhia ^b,c   Leboeuf, Marylene ^a   Beltrão, Monique ^a   Lira, Sérgio A ^a   Heym, Kenneth M ^f   Bigley, Venetia ^g   Collin, Matthew ^g   Manz, Markus G ^d   McClain, Kenneth ^b,c   Merad, Miriam ^a   Allen, Carl E ^b,c   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e ROCKEFELLER UNIVERSITY   (United States)

^f Division of Pediatric Hematology Oncology Department of Pediatrics Baylor College of Medicine ^*  (United States)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD14 ANTIGEN; CD34 ANTIGEN; GLYCOPROTEIN P 15095; LANGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAF V600E GENE; CELL DIFFERENTIATION; CELL INFILTRATION; CHILD; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HEMATOPOIETIC STEM CELL; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL HISTIOCYTOSIS; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRECURSOR; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD34; ANTIGENS, SURFACE; BONE MARROW; CELL DIFFERENTIATION; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMATOPOIETIC STEM CELLS; HISTIOCYTOSIS, LANGERHANS-CELL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFANT; LECTINS, C-TYPE; MALE; MANNOSE-BINDING LECTINS; MICE; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; TREATMENT OUTCOME;

EID: 84897944839     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20130977     Document Type: Article

References (38)

1. Allen, C.E., L. Li, T.L. Peters, H.C. Leung, A. Yu, T.K. Man, S. Gurusiddappa, M.T. Phillips, M.J. Hicks, A. Gaikwad, et al. 2010. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J. Immunol. 184:4557-4567. http://dx.doi.org/10.4049/jimmunol.0902336
2. Arceci, R.J. 1999. The histiocytoses: the fall of the Tower of Babel. Eur. J. Cancer. 35:747-767. http://dx.doi.org/10.1016/S0959-8049(99)00039-83
3. Badalian-Very, G., J.A. Vergilio, B.A. Degar, L.E. MacConaill, B. Brandner, M.L. Calicchio, F.C. Kuo, A.H. Ligon, K.E. Stevenson, S.M. Kehoe, et al. 2010. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 116:1919-1923. http://dx.doi.org/10.1182/blood-2010-04-279083
4. Bernard, F., C. Thomas, Y. Bertrand, M. Munzer, J. Landman Parker, M. Ouache, V.M. Colin, Y. Perel, P. Chastagner, C. Vermylen, and J. Donadieu. 2005. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur. J. Cancer. 41:2682-2689. http://dx.doi.org/10.1016/j.ejca.2005.02.007
5. Birbeck, M.S.C., A.S. Breathnach, and J.D. Everall. 1961. An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cell) in vitiligo. J. Invest. Dermatol. 37:51-64. http://dx.doi.org/10.1038/jid.1961.7
6. Chang, S.Y., H.R. Cha, J.H. Chang, H.J. Ko, H. Yang, B. Malissen, M. Iwata, and M.N. Kweon. 2010. Lack of retinoic acid leads to increased langerin-expressing dendritic cells in gut-associated lymphoid tissues. Gastroenterology. 138:1468-1478. http://dx.doi.org/10.1053/j.gastro.2009.11.006
7. Chapman, P.B., A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, et al. BRIM-3 Study Group. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-2516. http://dx.doi.org/10.1056/NEJMoa1103782
8. Chikwava, K., and R. Jaffe. 2004. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr. Dev. Pathol. 7:607-614. http://dx.doi.org/10.1007/s10024-004-3027-z da
9. Costa, C.E., N.E. Annels, C.M. Faaij, R.G. Forsyth, P.C. Hogendoorn, and R.M. Egeler. 2005. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J. Exp. Med. 201:687-693. http://dx.doi.org/10.1084/jem.20041785
10. Dankort, D., E. Filenova, M. Collado, M. Serrano, K. Jones, and M. McMahon. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21:379-384. http://dx.doi.org/10.1101/gad.1516407
11. de Graaf, J.H., R.Y. Tamminga, A. Dam-Meiring, W.A. Kamps, and W. Timens. 1996. The presence of cytokines in Langerhans' cell histiocytosis. J. Pathol. 180:400-406. http://dx.doi.org/10.1002/(SICI)1096-9896(199612)180:4<400::AID-PATH701>3.0.CO;2-W
12. Gadner, H., N. Grois, M. Arico, V. Broadbent, A. Ceci, A. Jakobson, D. Komp, J. Michaelis, S. Nicholson, U. Pötschger, et al.; Histiocyte Society. 2001. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J. Pediatr. 138:728-734. http://dx.doi.org/10.1067/mpd.2001.111331
13. Gadner, H., N. Grois, U. Pötschger, M. Minkov, M. Aricò, J. Braier, V. Broadbent, J. Donadieu, J.I. Henter, R. McCarter, and S. Ladisch; Histiocyte Society. 2008. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 111:2556-2562. http://dx.doi.org/10.1182/blood-2007-08-106211
14. Ginhoux, F., M.P. Collin, M. Bogunovic, M. Abel, M. Leboeuf, J. Helft, J. Ochando, A. Kissenpfennig, B. Malissen, M. Grisotto, et al. 2007. Bloodderived dermal langerin+ dendritic cells survey the skin in the steady state. J. Exp. Med. 204:3133-3146. http://dx.doi.org/10.1084/jem.20071733
15. Grois, N., Y. Tsunematsu, A.J. Barkovich, and B.E. Favara. 1994. Central nervous system disease in Langerhans cell histiocytosis. Br. J. Cancer Suppl. 23:S24-S28.
16. Haroche, J., F. Charlotte, L. Arnaud, A. von Deimling, Z. Hélias-Rodzewicz, B. Hervier, F. Cohen-Aubart, D. Launay, A. Lesot, K. Mokhtari, et al. 2012. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 120:2700-2703. http://dx.doi.org/10.1182/blood-2012-05-430140
17. Haroche, J., F. Cohen-Aubart, J.F. Emile, L. Arnaud, P. Maksud, F. Charlotte, P. Cluzel, A. Drier, B. Hervier, N. Benameur, et al. 2013. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 121:1495-1500. http://dx.doi.org/10.1182/blood-2012-07-446286
18. Hicks, J., and C.M. Flaitz. 2005. Langerhans cell histiocytosis: current insights in a molecular age with emphasis on clinical oral and maxillofacial pathology practice. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 100:S42-S66. http://dx.doi.org/10.1016/j.tripleo.2005.06.016
19. Kansal, R., L. Quintanilla-Martinez, V. Datta, J. Lopategui, G. Garshfield, and B.N. Nathwani. 2013. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer. 52:99-106. http://dx.doi.org/10.1002/gcc.22010
20. Kissenpfennig, A., S. Aït-Yahia, V. Clair-Moninot, H. Stössel, E. Badell, Y. Bordat, J.L. Pooley, T. Lang, E. Prina, I. Coste, et al. 2005. Disruption of the langerin/CD207 gene abolishes Birbeck granules without a marked loss of Langerhans cell function. Mol. Cell. Biol. 25:88-99. http://dx.doi.org/10.1128/MCB.25.1.88-99.2005
21. Kondo, M., A.J. Wagers, M.G. Manz, S.S. Prohaska, D.C. Scherer, G.F. Beilhack, J.A. Shizuru, and I.L. Weissman. 2003. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 21:759-806. http://dx.doi.org/10.1146/annurev.immunol.21.120601.141007
22. Lichtenstein, L. 1953. Histiocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Schüller-Christian disease as related manifestations of a single nosologic entity. AMA Arch. Pathol. 56:84-102.
23. Merad, M., F. Ginhoux, and M. Collin. 2008. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 8:935-947. http://dx.doi.org/10.1038/nri2455
24. Merad, M., P. Sathe, J. Helft, J. Miller, and A. Mortha. 2013. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31:563-604. http://dx.doi.org/10.1146/annurev-immunol-020711-074950
25. Nezelof, C., F. Basset, and M.F. Rousseau. 1973. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine. 18:365-371.
26. Pineles, S.L., G.T. Liu, X. Acebes, J. Arruga, S. Nasta, R. Glaser, M. Pramick, F. Fogt, P.L. Roux, and R.E. Gausas. 2011. Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J. Neuroophthalmol. 31:217-223. http://dx.doi.org/10.1097/WNO.0b013e31820a204e
27. Rodriguez-Galindo, C., M. Jeng, P. Khuu, M.B. McCarville, and S. Jeha. 2008. Clofarabine in refractory Langerhans cell histiocytosis. Pediatr. Blood Cancer. 51:703-706. http://dx.doi.org/10.1002/pbc.21668
28. Sahm, F., D. Capper, M. Preusser, J. Meyer, A. Stenzinger, F. Lasitschka, A.S. Berghoff, A. Habel, M. Schneider, A. Kulozik, et al. 2012. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 120:e28-e34. http://dx.doi.org/10.1182/blood-2012-06-429597
29. Satoh, T., A. Smith, A. Sarde, H.C. Lu, S. Mian, C. Trouillet, G. Mufti, J.F. Emile, F. Fraternali, J. Donadieu, and F. Geissmann. 2012. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE. 7:e33891. http://dx.doi.org/10.1371/journal.pone.0033891
30. Schnittger, S., U. Bacher, T. Haferlach, N. Wendland, M. Ulke, F. Dicker, V. Grossmann, C. Haferlach, and W. Kern. 2012. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood. 119:3151-3154. http://dx.doi.org/10.1182/blood-2011-10-383323
31. Senechal, B., G. Elain, E. Jeziorski, V. Grondin, N. Patey-Mariaud de Serre, F. Jaubert, K. Beldjord, A. Lellouch, C. Glorion, M. Zerah, et al. 2007. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 4:e253. http://dx.doi.org/10.1371/journal.pmed.0040253
32. Stover, D.G., S. Alapati, O. Regueira, C. Turner, and J.A. Whitlock. 2008. Treatment of juvenile xanthogranuloma. Pediatr. Blood Cancer. 51:130-133. http://dx.doi.org/10.1002/pbc.21523
33. Valladeau, J., O. Ravel, C. Dezutter-Dambuyant, K. Moore, M. Kleijmeer, Y. Liu, V. Duvert-Frances, C. Vincent, D. Schmitt, J. Davoust, et al. 2000. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 12:71-81. http://dx.doi.org/10.1016/S1074-7613(00)80160-0
34. Verdijk, P., R. Dijkman, E.I. Plasmeijer, A.A. Mulder, W.H. Zoutman, A. Mieke Mommaas, and C.P. Tensen. 2005. A lack of Birbeck granules in Langerhans cells is associated with a naturally occurring point mutation in the human Langerin gene. J. Invest. Dermatol. 124:714-717. http://dx.doi.org/10.1111/j.0022-202X.2005.23645.x
35. Verma, S., W.O. Greaves, F. Ravandi, N. Reddy, C.E. Bueso-Ramos, S. O'Brien, D.A. Thomas, H. Kantarjian, L.J. Medeiros, R. Luthra, and K.P. Patel. 2012. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am. J. Clin. Pathol. 138:153-156. http://dx.doi.org/10.1309/AJCPL0OPXI9LZITV
36. Willman, C.L., L. Busque, B.B. Griffith, B.E. Favara, K.L. McClain, M.H. Duncan, and D.G. Gilliland. 1994. Langerhans'-cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N. Engl. J. Med. 331:154-160. http://dx.doi.org/10.1056/NEJM199407213310303
37. Yu, R.C., C. Chu, L. Buluwela, and A.C. Chu. 1994. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 343:767-768. http://dx.doi.org/10.1016/S0140-6736(94)91842-2
38. Zahner, S.P., J.M. Kel, C.A. Martina, I. Brouwers-Haspels, M.A. van Roon, and B.E. Clausen. 2011. Conditional deletion of TGF-R1 using Langerin-Cre mice results in Langerhans cell deficiency and reduced contact hypersensitivity. J. Immunol. 187:5069-5076. http://dx.doi.org/10.4049/jimmunol.1101880